ACI

ALBERTSONS COMPANIES INC

Consumer Defensive | Mid Cap

$0.33

EPS Forecast

$18,809

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-11-30

Albertsons at the Helm: ACI Delivers 2025 Results, With an Extra Week of Data and a Roadmap for 2026

In a year when the sector wrestled with pharmacy headwinds and macro headwinds alike, ACI reported its fiscal 2025 outcomes alongside a dividends-and-buybacks push, a digital push, and a cautiously optimistic revenue forecast for fiscal 2026. Ticker: ACI. Key metrics teased here include EPS, earnings surprise dynamics, and the looming EPS consensus conversations that will follow the company into the new year.

Overview: One extra week, two big narratives

Albertsons Companies, Inc. (NYSE: ACI) reported fourth-quarter and full-year results for fiscal 2025, which closed February 28, 2026. The quarter benefited from an extra week, with net sales and other revenue totaling $20.3 billion for the 13 weeks, versus $18.8 billion in the prior-year 12-week period. Management attributed roughly $1.4 billion of that delta to the additional week, highlighting the quarterly delta as a reminder that timing can masquerade as trend.

Identical-slice growth for the quarter was 0.7%, with digital sales rising 16% and loyalty enrollment expanding 12% to 51.2 million members. The company reaffirmed a focus on the customer value proposition, digital and loyalty investments, and productivity initiatives as it positions for fiscal 2026.

From a profitability standpoint, GAAP results told a different story: a net loss of $481 million, or $(0.94) per share, which included a $600 million charge (net of tax) related to the Opioid Settlement Framework—a reminder that relief in the grind of quarterly results often comes with policy-related charges. On an adjusted basis, net income was $252 million, or $0.48 per share, with Adjusted EBITDA of $903 million for the quarter.

Fiscal 2025 Highlights: The full-year rhythm

  • Identical sales rose 2.0%;
  • Digital sales climbed 21% for the year;
  • Net income was $217 million, or $0.40 per share;
  • Adjusted net income totaled $1,209 million, or $2.18 per share;
  • Adjusted EBITDA reached $3,902 million.

The year’s clean accounting narrative (adjusted metrics) paints a more favorable path than the GAAP print might suggest, thanks to the ongoing adjustments that strip out one-time charges and settlement-related headwinds.

Leadership perspective and strategic posture

“Fiscal 2025 was a year of disciplined execution and resilience, as we closed the year with a solid fourth quarter that delivered strong Adjusted EBITDA despite meaningful top-line pharmacy-related headwinds,” said Susan Morris, CEO of Albertsons Companies.

Her commentary underscores a company that sees progress where it can measure it—digital growth, loyalty expansion, and profitability on an adjusted basis—while acknowledging pharmacy pricing headwinds intensified by the Inflation Reduction Act and sector mix shifts. The company’s messaging centers on strengthening the customer value proposition, accelerating digital capabilities, and building a productivity engine that could compound earnings growth and cash flow in fiscal 2026.

Fiscal 2026 Outlook: Where the revenue forecast meets the unknowns

Albertsons signaled a continued path toward earnings growth and cash generation, aiming to balance robust shareholder returns with long-term investments. The release emphasizes a deliberate focus on productivity and the foundational capabilities that support sustainable growth. Notably, the publication frames the outlook around EPS growth and Adjusted EBITDA, with the aspiration of delivering long-term shareholder value even as the pharmacy environment remains a source of volatility.

Analysts and investors will be watching for a formal EPS consensus versus management’s trajectory, and for a clear revenue forecast that can be reconciled with the extra-week dynamics that periodically distort quarterly comparisons. The company did not publish a specific numeric EPS consensus in the release, but it did articulate a framework: grow earnings, drive cash flow, and support a $2 billion remaining share repurchase authorization alongside a 13% dividend increase.

Implications for Albertsons and sector peers

The quarterly cadence here matters less for the headline than for what it says about execution discipline and capital allocation. An extra week’s contribution to net sales and the resilience of the adjusted earnings machine suggest the company is capable of sustaining higher digital penetration and loyalty engagement even as it contends with inflation-driven cost pressures and pharmacy headwinds.

For peers in the grocery and broader food retail ecosystem, the message is twofold. First, the market reward for disciplined capital allocation—dividends, buybacks, and investment in digital loyalty programs—remains intact. Second, the margin of error in a high-IR environment tightens, making the path to a clean EPS beat more dependent on operational leverage and favorable mix, not just top-line growth. In other words, when the wind shifts, the company that can point to durable Adjusted EBITDA expansion and cash flow will outperform, even if the raw GAAP narrative is messy.

In the near term, investors will weigh how much of fiscal 2026’s success depends on sustaining digital growth (already running in the high single to low double digits) and whether the company can translate this into steadier cash flow in the face of ongoing regulatory and policy-driven pricing dynamics in its pharmacy channel.

Takeaway

Albertsons’ fiscal 2025 results confirm a company that is aggressively steering toward higher-margin, digitally enabled growth, even as settlement charges and regulatory headwinds intrude on GAAP results. The EPS narrative will be central to the stock’s drift in the new year, especially around the EPS consensus and the revenue forecast for fiscal 2026. The quarter’s numbers—adjusted EBITDA strength, digital gains, and loyalty expansion—offer a plausible runway for sustainable earnings growth, but the road remains contested where pharmacy pricing and external headwinds bite. For investors, the key is whether the guideposts for 2026 translate into a durable path to cash flow and a credible long-run return story in the face of sector-wide pressures.

A pun-free forecast would be that Albertsons is trying to bake value into the product mix while trading on a robust dividend and a patient buyback. The market will test that recipe against peers’ attempts at similar digital-enhancement plays, with the next quarterly print likely to be judged on the precise rhythm between adjusted earnings and the unpredictable cadence of external charges.

Disclosure: This analysis references Albertsons Companies, Inc. earnings data and outlook. Ticker: ACI. Keywords for context: EPS, earnings surprise, EPS consensus, revenue forecast.